Unknown

Dataset Information

0

Clinical efficacy of nivolumab is associated with tertiary lymphoid structures in surgically resected primary tumors of recurrent gastric cancer.


ABSTRACT: Nivolumab, an immune checkpoint blocker, has been approved for advanced gastric cancer (GC), but predictive factors of nivolumab's efficacy in patients with GC, especially immune cells such as tissue-resident memory T cells or those forming tertiary lymphoid structures (TLS), remain unclear. Tissue samples were obtained from surgically resected specimens of patients with GC who were treated with nivolumab as third-line or later treatment. Immunohistochemical staining was performed to detect the presence of TLS and CD103+ T cells and assess the association between TLSs and response to nivolumab treatment. A total of 19 patients were analyzed. In patients with partial response (PR) to nivolumab, numerous TLS were observed, and CD103+ T cells were found in and around TLS. Patients with many TLS experienced immune-related adverse events more often than those with few TLS (p = 0.018). The prognosis of patients with TLS high was better than those with TLS low. Patients with a combination of TLS high and CD103 high tended to have a better prognosis than other groups. Our results suggested that TLS status might be a predictor of nivolumab effectiveness.

SUBMITTER: Mori T 

PROVIDER: S-EPMC8741034 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| 109483 | ecrin-mdr-crc
| S-EPMC8362934 | biostudies-literature
| S-EPMC8498832 | biostudies-literature
| S-EPMC8088970 | biostudies-literature
| S-EPMC10770129 | biostudies-literature
| S-EPMC8425751 | biostudies-literature
2021-11-22 | GSE188895 | GEO
| S-EPMC8762581 | biostudies-literature
| S-EPMC7400769 | biostudies-literature
| S-EPMC6236051 | biostudies-other